KVUE · 8-K · 20260806PR000141
Regulatory Approval Milestones
Kenvue Inc. · 2026-08-06 · Importance 31 · Surprise 42 · In source text
The U.S. Food and Drug Administration approved Tylenol with Naproxen, Kenvue’s fixed-dose OTC combination of 650 mg acetaminophen and 220 mg naproxen sodium. The product was supported by eight clinical studies and received a three-year exclusivity period. Kenvue expects the product to become available soon at major U.S. retailers nationwide.
Key facts
- Kenvue received U.S. Food and Drug Administration approval for Tylenol with Naproxen, the first and only OTC fixed-dose combination of acetaminophen and naproxen sodium. source
- Tylenol with Naproxen is supported by eight clinical studies and was granted a three-year exclusivity period. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Kenvue received U.S. Food and Drug Administration approval for Tylenol with Naproxen, the first and only OTC fixed-dose combination of… |
| revenue | positive | committed | — | Tylenol with Naproxen is supported by eight clinical studies and was granted a three-year exclusivity period. |